Andrew Laslett


  • +61 (3) 9518 5911

Research interests

Laslett Group’s research projects aim to develop tools, biomaterials and assays that enable the enrichment of hPSCs as input populations for optimised differentiation systems and the stringent identification and removal of unsafe tumorigenic cells in end-point pre-clinical cell populations.

Andrew Laslett’s group is also a joint appointment with CSIRO.

Featured Publications

Authors Title Published In

Harvey AJ, O’Brien C, Lambshead J, Sheedy JR, Rathjen J, Laslett AL, Gardner DK.

Physiological oxygen culture reveals retention of metabolic memory in human induced pluripotent stem cells.

PLoS One. 2018 Mar 15;13(3):e0193949. doi: 10.1371/journal.pone.0193949. eCollection 2018.

Lambshead JW, Meagher L, Goodwin J, Labonne T, Ng E, Elefanty A, Stanley E, O’Brien CM, Laslett AL.

Long-term maintenance of human pluripotent stem cells on cRGDfK-presenting synthetic surfaces.

Sci Rep. 2018;8(1):701. doi:10.1038/s41598-018-19209-0. Epub 2018 Jan 15.

Trusler O, Huang Z, Goodwin J, Laslett AL.

Cell surface markers for the identification and study of human naive pluripotent stem cells.

Stem Cell Res. 2017 Dec 2;26:36-43. doi: 10.1016/j.scr.2017.11.017. [Epub ahead of print]

Liu X, Nefzger CM, Rossello FJ, Chen J, Knaupp AS, Firas J, Ford E, Pflueger J, Paynter JM, Chy HS, O’Brien CM, Huang C, Mishra K, Hodgson-Garms M, Jansz N, Williams SM, Blewitt ME, Nilsson SK, Schittenhelm RB, Laslett AL, Lister R, Polo JM.

Comprehensive characterization of distinct states of human naive pluripotency generated by reprogramming.

Nat Methods. 2017 Nov;14(11):1055-1062. doi: 10.1038/nmeth.4436. Epub 2017 Sep 25.

Murphy AR, Ghobrial I, Jamshidi P, Laslett AL, O’Brien CM, Cameron NR.

Tailored emulsion-templated porous polymer scaffolds for iPSC-derived human neural precursor cell culture.

Polym Chem. 2017 Oct;8:351-7. doi: 10.1039/C7PY01375B.

Murphy AR, Laslett AL, O’Brien CM and Cameron, NR.

Scaffolds for 3D in vitro culture of neural lineage cells.

Acta Biomater. 2017 May;54:1-20. doi: 10.1016/j.actbio.2017.02.046. Epub 2017 Mar 1.

O’Brien CM, Chy HS, Zhou Q, Blumenfeld S, Lambshead JW, Liu X, Kie J, Capaldo BD, Chung TL, Adams TE, Phan T, Bentley JD, McKinstry WJ, Oliva K, McMurrick PJ, Wang YC, Rossello FJ, Lindeman GJ, Chen D, Jarde T, Clark AT, Abud HE, Visvader JE, Nefzger CM, Polo JM, Loring JF, Laslett AL.

New monoclonal antibodies to defined cell surface proteins on human pluripotent stem cells. 

Stem Cells. 2017 Mar;35(3):626-640. doi: 10.1002/stem.2558. Epub 2017 Jan 19.

Wang YC, Stein JW, Lynch CL, Tran HT, Lee CY, Coleman R, Hatch A, Antontsev VG, Chy HS, O’Brien CM, Murthy SK, Laslett AL, Peterson SE, Loring JF.

Glycosyltransferase ST6GAL1 contributes to the regulation of pluripotency in human pluripotent stem cells.

Sci Rep. 2015 Aug 25;5:13317. doi: 10.1038/srep13317.

Mason EA, Mar JC, Laslett AL, Pera MF, Quackenbush J, Wolvetang E, Wells CA.

Gene expression variability as a unifying element of the pluripotency network.

Stem Cell Reports. 2014 Aug 12;3(2):365-77. doi: 10.1016/j.stemcr.2014.06.008. Epub 2014 Jul 25.

Xu Y, Liu L, Laslett AL, Esteban MA.

Cell Reprogramming: Into the groove.

Nat Mater. 2013 Dec;12(12):1082-4. doi: 10.1038/nmat3821.

Tian W, Wang Y, Xu Y, Guo X, Wang B, Sun L, Liu L, Cui F, Zhuang Q, Bao X, et al.

The hypoxia-inducible factor renders cancer cells more sensitive to vitamin C-induced toxicity.

J Biol Chem. 2014 Feb 7;289(6):3339-51. doi: 10.1074/jbc.M113.538157. Epub 2013 Dec 26.

Polanco JC, Wang B, Zhou Q, Chy H, O’Brien C, Laslett AL.

Enrichment and purging of human embryonic stem cells by detection of cell surface antigens using the monoclonal antibodies TG30 and GCTM-2.

J Vis Exp. 2013 Dec 6;(82):50856. doi: 10.3791/50856.

Polanco JC, Laslett AL.

Safety assessment of reprogrammed cells prior to clinical applications: Potential approaches to eliminate teratoma formation.

Puripotent Stem Cells. 2013;25:555-566. doi:10.5772/54400

Polanco JC, Ho MSH, Wang B, Zhou Q, Wolvetang E, Mason E, Wells CA, Kolle G, Grimmond SM, Bertoncello I, et al.

Identification of unsafe human induced pluripotent stem cell lines using a robust surrogate assay for pluripotency.

Stem Cells. 2013 Aug;31(8):1498-510. doi: 10.1002/stem.1425.

Lambshead JW, Meagher L, O’Brien C, Laslett AL.

Defining synthetic surfaces for human pluripotent stem cell culture.

Cell Regen. 2013;2(1):7. doi: 10.1186/2045-9769-2-7. Epub 2013 Nov 22.

Nazor KL, Altun G, Lynch C, Tran H, Harness JV, Slavin I, Garitaonandia I, Mueller F-J, Wang Y-C, Boscolo FS, et al.

Recurrent variations in DNA methylation in human pluripotent stem cells and their differentiated derivatives.

Cell Stem Cell. 2012 May 4;10(5):620-34. doi: 10.1016/j.stem.2012.02.013.

Laurent LC, Ulitsky I, Slavin I, Tran H, Schork A, Morey R, Lynch C, Harness JV, Lee SH, Barrero MJ, et al.

Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture.

Cell Stem Cell. 2011 Jan 7;8(1):106-18. doi: 10.1016/j.stem.2010.12.003.

Kolle G, Shepherd JL, Gardiner B, Kassahn KS, Cloonan N, Wood DLA, Nourbakhsh E, Taylor DF, Wani S, Chy HS, et al.

Deep-transcriptome and ribonome sequencing redefines the molecular networks of pluripotency and the extracellular space in human embryonic stem cells.

Genome Res. 2011 Dec; 21(12): 2014–2025. doi: 10.1101/gr.119321.110

Amps K, Andrews PW, Anyfantis G, Armstrong L, Avery S, Baharvand H, Baker J, Baker D, Munoz MB, Beil S, et al.

Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage.

Nat Biotechnol. 2011 Nov 27;29(12):1132-44. doi: 10.1038/nbt.2051.

Laurent LC, Nievergelt CM, Lynch C, Fakunle E, Harness JV, Schmidt U, Galat V, Laslett AL, Otonkoski T, Keirstead HS, et al.

Restricted ethnic diversity in human embryonic stem cell lines.

Nat Methods. 2010 Jan;7(1):6-7. doi: 10.1038/nmeth0110-06.

Herszfeld D, Wolvetang E, Langton-Bunker E, Chung TL, Filipczyk AA, Houssami S, Jamshidi P, Koh K, Laslett AL, Michalska A, et al.

CD30 is a survival factor and a biomarker for transformed human pluripotent stem cells.

Nat Biotechnol. 2006 Mar;24(3):351-7. Epub 2006 Feb 26.